22 completed, 5 unknown, 2 active not recruiting, 1 terminated. 31 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 31 | Completed 22, Unknown 5, Active not recruiting 2, Terminated 1, Withdrawn 1 |
Follow Forxiga: new trials by email Literature Review of Forxiga trials Research Report on Forxiga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure Dapagliflozin - Heart Failure | Phase 4 | Active not recruiting | Fundación para la Investigación del Hospital Clínico de Valencia | 31 | 2024-07-30 | 2026-09-09 |
| The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes Dapagliflozin 10mg Tab, Metformin 1000 mg (ttd), Placebo - Obesity, Dapagliflozin Adverse Reaction | Phase 4 | Active not recruiting | Oman Ministry of Health | 150 | 2024-04-22 | 2025-03-26 |
| Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control DA-2811, Forxiga - Diabetes Mellitus | Phase 4 | Completed | Dong-A ST Co., Ltd. | 231 | 2023-04-25 | 2025-03-14 |
| Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS) Dapagliflozin, Placebo - Anemia, Heart Failure | Phase 4 | Unknown | Xiangtan Central Hospital | 1990 | 2021-08-06 | 2024-07-01 |
| Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Dapagliflozin 10mg Tab, Placebo, Withings BPM Connect - Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria | Phase 4 | Completed | University Medical Center Groningen | 20 | 2021-05-11 | 2024-04-22 |
| Dapagliflozin on Volume Vascular Outcomes. Dapagliflozin, Placebo - Heart Failure，Congestive | Phase 4 | Completed | Frank Ruschitzka | 80 | 2021-02-15 | 2024-11-12 |
| Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery Dapagliflozin 10 MG, Placebos - Diabetes Mellitus, Type 2, Cardiac Surgery | Phase 4 | Unknown | Hongchang Guo | 500 | 2021-01-01 | 2021-10-07 |
| Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy Dapagliflozin, Sacubitril-Valsartan, Beta blocker - Hypotension, Heart Failure | Phase 4 | Completed | Cheng-Hsin General Hospital | 78 | 2020-05-29 | 2021-08-02 |
| Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Forxiga - Nephropathy, Hypoxia | Phase 4 | Completed | Steno Diabetes Center Copenhagen | 30 | 2020-02-01 | 2021-02-03 |
| Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity Dapagliflozin, Dapagliflozin plus Metformin XR, Metformin XR - Obesity | Phase 4 | Unknown | University of Guadalajara | 33 | 2019-07-30 | 2023-05-23 |
| Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 dapagliflozin, Placebo - Type 2 Diabetes Mellitus, Myocardial Fibrosis | Phase 4 | Completed | University of Washington | 62 | 2019-02-26 | 2023-12-29 |
| Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension Dapagliflozin, Placebo - Cap - Hypertension | Phase 4 | Unknown | University of Guadalajara | 20 | 2019-02-14 | 2020-12-28 |
| Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy Dapagliflozin 10 mg, Sitagliptin 100mg - Type 2 Diabetes, Ketonemia | Phase 4 | Completed | The University of Hong Kong | 60 | 2017-08-16 | 2021-04-29 |
| Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? Dapagliflozin, Placebo - Type 2 Diabetes, Left Ventricular Hypertrophy | Phase 4 | Completed | University of Dundee | 66 | 2017-02-14 | 2019-07-09 |
| Effect of Anti-diabetic Drugs on Glycemic Variability Dapagliflozin, Gliclazide MR - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Centro de Diabetes Curitiba Ltda | 135 | 2016-10-01 | 2020-03-04 |
| Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes. Dapagliflozin, Placebo - Diabetes Mellitus | Phase 4 | Terminated | Hellenic Society for Medical Education | 85 | 2016-10-01 | 2019-12-03 |
| Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Dapagliflozin, Placebo - Prediabetes, Impaired Fasting Glucose | Phase 4 | Completed | University of Guadalajara | 24 | 2016-10-01 | 2020-10-28 |
| A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients Dapagliflozin, Standard of Care - Type 2 Diabetes Mellitus | Phase 4 | Completed | University of Liverpool | 632 | 2016-08-25 | 2026-02-20 |
| Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice Dapagliflozin, Metformin - Diabetes Mellitus Type 2 | Phase 4 | Withdrawn | AstraZeneca | 2016-07-01 | 2016-05-20 | |
| Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2) Dapagliflozin, Rosuvastatin - Diabetes Mellitus, Type 2, Hypercholesterolemia | Phase 4 | Completed | Amsterdam UMC, location VUmc | 12 | 2016-05-01 | 2020-08-04 |
Showing 20 of 31. Sign in to see all of them.
Diabetes Mellitus, Type 2 (15) · Diabetes Mellitus (8) · Heart Failure (5) · Hyperglycemia (2) · Obesity (2) · Prediabetic State (2) · Albuminuria (1) · Anemia (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus, Type 1 (1) · Diabetic Nephropathies (1) · Diabetic Neuropathies (1) · Glucose Intolerance (1)
University of Guadalajara (4) · AstraZeneca (2) · Seoul National University Bundang Hospital (2) · University of Dundee (2) · Amsterdam UMC, location VUmc (1) · Centro de Diabetes Curitiba Ltda (1) · Cheng-Hsin General Hospital (1) · Dong-A ST Co., Ltd. (1) · Frank Ruschitzka (1) · Fundación para la Investigación del Hospital Clínico de Valencia (1) · Hellenic Society for Medical Education (1) · Hongchang Guo (1) · Lund University (1) · M.H.H. Kramer (1) · Oman Ministry of Health (1)
Mexico (4) · Netherlands (4) · South Korea (3) · United Kingdom (3) · China (2) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Oman (1)
Alexander Ametov, prof., MD (1) · Allan Struthers, MD, FRCP (1) · Andre GD Vianna, MD (1) · Bo Ahren, MD PhD (1) · Chengming Wang, Ph.D. (1) · Chim Lang, MD, FRCP (1) · Chonglun Zhou, M.D. (1) · Fanghua Xu, M.D. (1) · Frank Ruschitzka, M.D. (1) · Graeme Houston, FRCR, MBBCh (1) · Hertzel C Gerstein, MD (1) · Hung-Yu Chang, MD (1) · Jagdeep Singh, MBBS (1)
PMID 27422625, PMID 28376855, PMID 28835229, PMID 29947099, PMID 31412874, PMID 31816432, PMID 32200854, PMID 32245746, PMID 32403130, PMID 32516291, PMID 32578850, PMID 33205810, PMID 33277990, PMID 33779938, PMID 34386735, PMID 34693515, PMID 35221224, PMID 35322793, PMID 38585865, PMID 38770818, PMID 38849829, PMID 38997620, PMID 40601599, PMID 41629250, PMID 42644318
2014 (3), 2015 (2), 2016 (1), 2019 (1)